Regulation · Australia

Is BPC-157 legal
in Australia?

Australia’s Poisons Standard names BPC-157. Here is the entry word for word, how the TGA put it there, and what the TGA did with it in 2026.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

BPC-157 is a Schedule 4 (prescription-only) poison in Australia, and Appendix D of the Poisons Standard names it as a poison that must not be possessed without authority. When the TGA scheduled it, with effect from 1 June 2024, it recorded that no approved product in Australia contained it. The TGA says importing, advertising, manufacturing and supplying unapproved peptide products is unlawful.

Key takeaways

  • The October 2026 Poisons Standard lists BPC-157 in Schedule 4, marked # for Appendix D, and as item 5 of Appendix D, clause 5: poisons that must not be possessed without authority.
  • A Schedule 4 poison may be supplied only by a doctor, dentist or vet in lawful practice, or by a pharmacist dispensing a legal prescription, with narrow exceptions (section 60).
  • The TGA’s delegate scheduled BPC-157 after 48 import referrals, citing a limited evidence basis, a largely uncharacterised toxicity profile and “research only” disclaimers.
  • Under the Therapeutic Goods Act 1989, importing or supplying therapeutic goods for use in humans that are not registered, listed, exempt or approved is an offence (section 19B).
  • In 2026 the TGA named BPC-157 in its peptide advisory, seized a product sold as a BPC-157 and TB-500 combination, and found no TB-500 in a tested product labelled with both.

01What does the Poisons Standard say about BPC-157?

The instrument in force is the Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). It was registered on 30 September and commenced on 1 October 2026. It names BPC-157 twice.

Schedule 4. Schedule 4 is headed “Prescription only medicines and prescription animal remedies”. The entry reads “# BPC-157.”, and a note to the Schedule explains the symbol: “Substances marked # are listed in Appendix D.”

Appendix D, clause 5. Clause 5 covers poisons “that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription).” BPC-157 is item 5.

Who may supply a Schedule 4 poison. Section 60 of the instrument says a Schedule 4 poison must not be supplied by anyone other than a medical practitioner, dental practitioner or veterinarian acting in the lawful practice of their profession, or a pharmacist dispensing a legal prescription. The remaining exceptions are narrow: limited emergency supply by a pharmacist to a patient already being treated with the poison, and wholesale supply to practitioners, pharmacists and other licensed people.

How the Standard becomes law. The Poisons Standard is a national model. Its explanatory statement says the Schedules “are incorporated by reference in State and Territory legislation”, which is where the supply and possession offences sit. The Commonwealth uses the scheduling as well: the Therapeutic Goods Act prohibits advertising prescription medicines containing Schedule 4 substances to consumers.

Part of the October 2026 StandardTextWhat it does
Schedule 4“# BPC-157.”Prescription only. The # flags a listing in Appendix D.
Appendix D, clause 5, item 5“BPC-157”Clause heading: “Poisons for which possession without authority is illegal”. Section 64(4) applies it “under the law of the jurisdiction in which the possession occurs”.
Index“BPC-157: Schedule 4, Appendix D, clause 5”Cross-reference to both entries.
Section 60Supply rules for every Schedule 4 poisonDoctor, dentist or vet in lawful practice, or a pharmacist on a legal prescription.

02How did BPC-157 become Schedule 4?

Through the TGA’s standard scheduling process, which ran from late 2023 to mid-2024. Two TGA notices hold the record.

1
The proposal

A delegate of the TGA’s Secretary proposed the two entries. The trigger, the TGA wrote, was 48 import referrals for BPC-157 since July 2022. The aim was to schedule it in line with other substances used for performance and image (PIEDs). Until then the Standard did not capture it.

2
Consultation and committee

The proposal drew 22 public submissions. All four written ones supported it; of 18 tick-box responses, 17 were supportive and 1 partly supportive. The Advisory Committee on Medicines Scheduling, at its 43rd meeting in November 2023, recommended the entries.

3
Interim decision, 3 April 2024

Comments were invited until 17 April. One submission arrived, and it supported the decision.

4
Final decision, 22 May 2024

The delegate confirmed the interim decision. The entries took effect on 1 June 2024.

The delegate’s reasons. The interim decision gives them in the delegate’s own words: “a limited evidence basis to support the putative therapeutic benefits, while the risk of misuse remains high”, and a toxicity profile that is “largely uncharacterised”. It also cites “the current practice of online vendors in promoting BPC-157 with the disclaimer ‘not for therapeutic use’ or ‘for research only’ to circumvent existing controls on therapeutic goods.”

The delegate noted “no evidence that BPC-157 is a psychoactive substance”. Appendix D was chosen because the substance “has significant potential for illicit diversion and/or abuse which does not warrant inclusion in Schedule 8 but warrants particular control of possession.” The committee recommended the 1 June 2024 date because no registered products were affected.

03What does the Therapeutic Goods Act add?

Scheduling decides who may supply and possess a substance. The Therapeutic Goods Act 1989 decides whether a product may be on the market at all.

What counts as a therapeutic good. The Act covers goods represented as being for “therapeutic use”, which it defines to include “influencing, inhibiting or modifying a physiological process in persons”. The TGA’s April 2026 advisory states that “peptide products are regulated as therapeutic goods in Australia”, and that unapproved ones are those not included in the Australian Register of Therapeutic Goods (ARTG).

The core offence. Section 19B makes it an offence to import, export, manufacture or supply in Australia therapeutic goods for use in humans unless they are registered or listed, exempt, or approved under sections 19 or 19A. The maximum is 12 months’ imprisonment, 1,000 penalty units or both. It rises to 5 years, 4,000 penalty units or both, where use of the goods has caused, or is likely to cause, harm or injury.

What counts as manufacture. In July 2026 the TGA said manufacture “includes any step in the manufacturing process, including applying a label to a blank vial, packaging for distribution, and storage of the products before they are in their final state.”

Labels. The April 2026 advisory says “research use only” disclaimers alone do not “change a product’s regulatory status”, “permit importation” or “remove advertising or supply obligations”. More: what “research use only” means. How stopped parcels are handled is on peptides seized by customs.

04What has the TGA done about BPC-157, and when?

From the first import referrals to the 2026 laboratory results. All entries come from TGA documents unless marked.

DateWhat happened
From 1 Jul 2022The TGA receives 48 referrals for importation of BPC-157.
Nov 2023The 43rd meeting of the Advisory Committee on Medicines Scheduling considers the proposal.
3 Apr 2024Interim decision: Schedule 4 and Appendix D, clause 5.
22 May 2024Final decision confirms both entries.
1 Jun 2024The entries take effect.
13 Apr 2026A TGA safety advisory lists BPC-157 first among its examples of unapproved peptide products, “often supplied in injectable form”.
7 May 2026The TGA warns that poorly labelled peptide imports will not be released, and that it will notify the Australian Border Force to seize and destroy them.
10 Jun 2026Unapproved peptide products join the TGA’s compliance priorities.
20 Jul 2026The TGA puts advertisers and sellers on notice and says labelling a blank vial counts as manufacture.
17 Aug 2026With NSW Police, the TGA announces the seizure of more than A$120,000 of peptide and anabolic steroid products, among them a combined BPC-157 and TB-500 product. Warrants were executed on 4 August.
1 Oct 2026The October 2026 Poisons Standard commences and carries both BPC-157 entries forward.
5 Nov 2026TGA testing finds no detectable TB-500 in a product from one brand labelled as BPC-157 and TB-500. The TGA states that most peptide products, “including BPC-157, TB-500 and melanotan I, are prescription-only medicines in Australia”.

The TGA reported the TB-500 result only. It did not say how much BPC-157 the product contained.

05How is BPC-157 treated in Australian sport?

Sport Integrity Australia describes BPC-157 as “a non-approved substance - prohibited at all times - and a specified substance” on the WADA Prohibited List. Its page adds: “A Therapeutic Use Exemption (TUE) would not be granted for the use of BPC-157, in any medical condition.”

In May 2026 the agency reminded athletes that under strict-liability rules they “are accountable for any prohibited substance in their system, no matter the source”. Detail: is BPC-157 banned in sport?

06What changed in 2026?

The legal status did not change. Enforcement did.

The October 2026 Standard, which replaced the June 2026 instrument, carries both BPC-157 entries forward. Its new entries included 11 new chemical entities in Schedule 4; two of them, somatrogon and lonapegsomatropin, were also added to Appendix D, clause 5.

Around the unchanged entries, the TGA made unapproved peptides a compliance priority. It warned that poorly labelled imports would be seized and destroyed, and it defined labelling a blank vial as manufacture. It executed warrants with state police and published laboratory results showing labels that did not match contents. For the rules that apply to every peptide, see are peptides legal in Australia?

07What we don’t know

State and territory detail. The offences and penalties for Appendix D poisons are set by each state’s and territory’s poisons law, which we have not summarised.

The ARTG itself. We could not search the ARTG, because tga.gov.au did not respond to our tools. The TGA’s 2024 decision recorded no approved products, and Sport Integrity Australia says BPC-157 is not listed on the ARTG.

Compound-level enforcement. The TGA’s releases describe seizures and notices by product type. They do not count actions involving BPC-157.

For the US and UK positions, see is BPC-157 legal? and is BPC-157 legal in the UK? The evidence on BPC-157 itself is in our BPC-157 research guide. Changes are logged in our regulatory changelog.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): section 60, Schedule 4 (and Note 2), Appendix D clause 5, index. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; full text read 18 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  2. Explanatory Statement to the Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026. Federal Register of Legislation, registered 30 Sep 2026; read 18 Nov 2026. api.prod.legislation.gov.au/v1/Documents(titleId='F2026L0132…
  3. TGA. Notice of interim decisions to amend (or not amend) the current Poisons Standard: ACMS #43, ACCS #37, Joint ACMS-ACCS #35 (November 2023), pp. 13–15 (BPC-157). Published 3 Apr 2024; read on the Internet Archive capture of 6 Nov 2025 (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/sites/default/files/2024-04/public-notice-of-…
  4. TGA. Notice of final decisions to amend (or not amend) the current Poisons Standard (November 2023), p. 10 (BPC-157). Published 22 May 2024; read on the Internet Archive capture of 21 Apr 2025. www.tga.gov.au/sites/default/files/2024-05/notice-final-deci…
  5. Therapeutic Goods Act 1989, section 3 (definitions) and section 19B. Federal Register of Legislation, Compilation No. 89 (5 Sep 2025), the latest compilation; read 18 Nov 2026. www.legislation.gov.au/C2004A03952/latest/text
  6. TGA. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Safety advisory, 13 Apr 2026; read on the Internet Archive capture of 10 Aug 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  7. TGA. TGA warning on the risks of importing unapproved peptide products. Safety alert, 7 May 2026; read on the Internet Archive capture of 25 Jul 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  8. TGA. TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response. Media release, 10 Jun 2026; read on the Internet Archive capture of 29 Oct 2026. www.tga.gov.au/news/media-releases/tga-strengthens-complianc…
  9. TGA. Unapproved peptide product promoters and suppliers are put on notice. Media release, 20 Jul 2026; read on the Internet Archive capture of 12 Sep 2026, the newest. www.tga.gov.au/news/media-releases/unapproved-peptide-produc…
  10. TGA. TGA flexes its muscle against illegal peptides and steroids. Media release, 17 Aug 2026; read on the Internet Archive capture of 11 Oct 2026, the newest. www.tga.gov.au/news/media-releases/tga-flexes-its-muscle-aga…
  11. TGA. TGA testing finds unapproved peptides do not contain what their labels claim. Safety alert, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  12. Sport Integrity Australia. BPC-157 information (cites the 2025 Prohibited List). Substance education page; read on the Internet Archive capture of 14 Sep 2026 (sportintegrity.gov.au timed out). www.sportintegrity.gov.au/what-we-do/anti-doping/substance-e…
  13. Sport Integrity Australia. Sport Integrity Australia warns athletes: peptides pose serious anti-doping and health risks. Media statement, May 2026; read on the Internet Archive capture of 8 Jun 2026. www.sportintegrity.gov.au/news/media-statements/2026-05/spor…

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is BPC-157 prescription-only in Australia?

Yes. It has been in Schedule 4 of the Poisons Standard, prescription-only medicines, since 1 June 2024. When it was scheduled, the TGA recorded that no approved product in Australia contained it.

What is Appendix D, clause 5 of the Poisons Standard?

A list of poisons that must not be possessed without authority, for example other than in accordance with a legal prescription. BPC-157 is item 5. State and territory laws give the Standard effect and set the penalties.

Why did the TGA schedule BPC-157?

The delegate cited 48 import referrals, “a limited evidence basis” for the claimed therapeutic benefits, a toxicity profile that is “largely uncharacterised”, a high risk of misuse, and “research only” disclaimers used to get around existing controls.

Does a “research use only” label change BPC-157’s status in Australia?

No. The TGA says such disclaimers alone do not change a product’s regulatory status, permit importation or remove advertising and supply obligations. The 2024 scheduling decision named those disclaimers as one of its reasons.

Is BPC-157 prohibited in Australian sport?

Yes. It is in WADA class S0, prohibited at all times, and Sport Integrity Australia says a therapeutic use exemption would not be granted for it in any medical condition.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page